As New York sees historic decrease in drug-related deaths, concerns rise on possible federal cuts
With threats of looming cuts at the federal level by President Trump's administration, local leaders that specialize in drug recovery and treatment services are sharing their concerns.
Recent reporting from the CDC shows New York saw a 32 percent decrease in drug-related deaths in 2024 compared to previous rates in 2023.
According to the CDC, approximately 77 percent of those deaths involved an opioid, such as heroin or fentanyl.
'I think we don't really know all the reasons why we see this dramatic decrease. We do know there have been several programs that have taken up more traction. Some of that is the overdose prevention education that the Rochester community and the country have invested in as well as the Naloxone distribution. It's also education around safer opioid prescribing practices, and access to medication like Buprenorphine and Methadone,' said Dr. Sarah Bolduc, chief medical officer for Trillium Health.
During the COVID-19 pandemic, drug overdose deaths surged to record levels. With the recent decline comes concern surrounding the uncertainty for continued supports from the federal government.
Leaders with Rochester-based Trillium Health and Common Ground Health both say it could put programs backed by those federal dollars in jeopardy nationwide.
'There will be no treatment services available for people who want to get into treatment. There will be no funds to continue the prevention education piece of this, which is very important in our communities. We must keep doing the work until we're told we can't do it anymore,' said Jackie Dozier, director of community health and well-being for Common Ground Health.
As both local agencies continue to work to meet the needs of the community, leaders say they are bracing for any possible changes in the future.
'I think we will continue to see more deaths and see less of a decline if we have less programming and support economically for this programming in the community. We believe it's correlated. We know that things like Naloxone work, and having more ready-access and people carrying it just so they can potentially help somebody that's potentially struggling on the street, I think that's very important and all of that takes funds,' said Dr. Bolduc.
Last week, hundreds of national researchers and health care providers issued a letter to Congress warning about the 'dire consequences' budget cuts would present for substance use and mental health programs in the U.S., specifically in overdose prevention.
More information from New York State on the CDC's latest report can be found here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Labcorp Holdings Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Labcorp Holdings (NYSE:LH) Second Quarter 2025 Results Key Financial Results Revenue: US$3.53b (up 9.5% from 2Q 2024). Net income: US$237.9m (up 16% from 2Q 2024). Profit margin: 6.7% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$2.85 (up from US$2.44 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Labcorp Holdings Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are up 8.7% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Labcorp Holdings. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Time Business News
9 hours ago
- Time Business News
BrainSim-X Launches Developer Platform for Neural Simulation Data
BrainSim-X announced the launch of a developer access program that allows researchers and app developers to integrate brain simulation data into their applications. More information about the platform is available at their official website . The Bangalore-based research initiative said the platform will focus on medical applications, particularly epilepsy research and neurological treatment development. Unlike typical API services, BrainSim-X requires developers to submit applications explaining their intended use cases before gaining access to the platform. Interested developers can request API credentials through their secure portal. The approval process takes approximately one week, with the organization reviewing each application to ensure it aligns with their medical research focus. One developer who has used the platform for three months described it as providing detailed neural activity data that requires significant technical expertise to implement properly. A detailed account of this developer's experience can be found in their comprehensive review . 'The platform generates large amounts of data that require powerful computing resources,' the developer said. 'It's designed for serious medical research rather than general app development.' The organization provides documentation and support for developers working on brain-computer interfaces, neuroscience research projects, and medical applications. Their research findings are available for review in published papers. Real-time data access became available recently, allowing developers to integrate live neural simulation feeds into their applications. The platform is intended for researchers studying brain activity patterns, testing neurological treatments, and developing diagnostic tools. BrainSim-X operates the service through a secure API that provides access to neural simulation data generated by their brain modeling platform. Technical requirements include high-memory computing systems capable of processing large neural datasets. Additional technical insights about the platform's capabilities can be found in this technical analysis . The research initiative says the developer program represents part of their commitment to making brain simulation technology accessible to the global research community. Applications are evaluated based on their potential contribution to medical research and neurological treatment development. BrainSim-X has not disclosed revenue generated from the developer platform, stating that funds support ongoing research activities. The organization expects demand for the platform to grow as more researchers learn about neural simulation applications in medical research. Future platform updates will include enhanced simulation capabilities and additional tools for analyzing neural activity patterns. BrainSim-X says the developer program differentiates it from commercial AI companies by focusing on open research collaboration rather than proprietary technology development. The platform supports research into cognitive enhancement, educational technology, and advanced diagnostic systems. Developers interested in accessing the platform must demonstrate relevant research experience and explain how they plan to use neural simulation data in their projects. BrainSim-X provides training resources to help developers understand neuroscience concepts necessary for effectively using the platform. The organization says it will continue expanding the developer program while maintaining focus on medical and scientific applications. Related Resources TIME BUSINESS NEWS
Yahoo
9 hours ago
- Yahoo
With 71% ownership of the shares, PureTech Health plc (LON:PRTC) is heavily dominated by institutional owners
Key Insights Institutions' substantial holdings in PureTech Health implies that they have significant influence over the company's share price A total of 11 investors have a majority stake in the company with 51% ownership Past performance of a company along with ownership data serve to give a strong idea about prospects for a business Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in PureTech Health plc (LON:PRTC) should be aware of the most powerful shareholder groups. With 71% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's take a closer look to see what the different types of shareholders can tell us about PureTech Health. See our latest analysis for PureTech Health What Does The Institutional Ownership Tell Us About PureTech Health? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. We can see that PureTech Health does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see PureTech Health's historic earnings and revenue below, but keep in mind there's always more to the story. Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. It looks like hedge funds own 5.2% of PureTech Health shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is Invesco Ltd. with 17% of shares outstanding. For context, the second largest shareholder holds about 5.6% of the shares outstanding, followed by an ownership of 5.2% by the third-largest shareholder. After doing some more digging, we found that the top 11 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. Insider Ownership Of PureTech Health The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own some shares in PureTech Health plc. It has a market capitalization of just UK£344m, and insiders have UK£16m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. General Public Ownership The general public-- including retail investors -- own 15% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. Public Company Ownership It appears to us that public companies own 4.0% of PureTech Health. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand PureTech Health better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for PureTech Health (of which 2 make us uncomfortable!) you should know about. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
